Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05252871 · ClinicalTrials.gov registry record · NA
Assessment of Three Basic Progressive Lens Designs
A NA study of Presbyopia, sponsored by Western University of Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT05252871: Completed NA study of Presbyopia, sponsored by Western University of Health Sciences.
NCT05252871 is a NA study of Presbyopia that has completed, run by Western University of Health Sciences. The registered enrollment target is 80 participants, below the 268-participant average among 38 other Presbyopia trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05252871, a NA study of Presbyopia, has completed, sponsored by Western University of Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial investigates the differences between three different progressive addition lens designs. It is a non-invasive double-masked randomized clinical investigation. For this study, 80 participants will be recruited.
Primary Outcome
Evaluate the adaptation to progressive lens designs through a "Satisfaction questionnaire" after 1 week of use of each of the 3 progressive addition lenses. Scale titles: Visual Quality Scale: A 5-point scale from a minimum value of 1 to a maximum score of 5. Higher scores mean better outcomes.
Conditions Studied
Interventions
- DEVICE Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating
Study Locations (1)
California
- Western University of Health Sciences - Pomona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-12-09 |
| Est. Completion | 2022-06-06 |
| Phase | NA |
What the finished NCT05252871 record still lists
NCT05252871 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 268-participant average among 38 other Presbyopia trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Presbyopia appearing as the primary indexed condition, and to 1 intervention - of which Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating is the first listed.
NCT05252871 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05252871 about?
NCT05252871 is a clinical study titled "Assessment of Three Basic Progressive Lens Designs". This clinical trial investigates the differences between three different progressive addition lens designs. It is a non-invasive double-masked randomized clinical investigation. For this study, 80 participants will be recruited.
What is the current status of trial NCT05252871?
This trial is currently completed. It is a NA study. The enrollment target is 80 participants. The study started on 2021-12-09. Estimated completion is 2022-06-06.
What conditions does trial NCT05252871 study?
This clinical trial studies the following conditions: Presbyopia.
What interventions are being tested in trial NCT05252871?
The interventions under investigation include: Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating (DEVICE).
Who is sponsoring clinical trial NCT05252871?
This trial is sponsored by Western University of Health Sciences, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05252871 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Presbyopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05252871's enrollment target sits among peer trials
80 18th of 38 higher than 21 of 38 other Presbyopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Presbyopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs
RECRUITING · NA
-
A Clinical Comparison of Proclear® 1 Day Multifocal and Clariti® 1 Day Multifocal 3 Add
RECRUITING · NA
-
Presbyopic Wear Experience With Multifocal Lenses Compared to Single Vision Lenses and Reading Glasses
RECRUITING · NA
-
Clinical Applications of Advanced Ophthalmic Imaging
RECRUITING · NA
-
Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix
ACTIVE NOT RECRUITING · NA
-
Clinical Evaluation of a Small Aperture Extended Depth of Focus Intraocular Lens
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI